A new medication therapy management model being rolled out by CMS will test strategies to improve medication use among Medicare beneficiaries enrolled in the Part D drug program.
A new medication therapy management (MTM) model being rolled out by CMS will test strategies to improve medication use among Medicare beneficiaries enrolled in the Part D drug program.
The Part D Enhanced MTM model will assess whether providing some Medicare prescription drugs plans with additional incentives and flexibilities granted to plan design will achieve better overall goals for MTM programs.
“Through this model, we are hopeful that Part D plans will invest in medication therapy management and identify new, effective strategies to optimize medication use and improve care coordination in Medicare,” Patrick Conway, MD, MSc, CMS acting principal deputy administrator and chief medical officer, said in a statement.
Some of the goals the program is looking to achieve include: improving compliance with medication protocols, including high-cost drugs; reducing medication-related problems; increasing patients’ knowledge of their medications to better achieve goals of therapy; and improving communication among prescribers, pharmacists, caregivers, and patients.
Testing for the model will begin January 1, 2017, with a 5-year performance period and will be tested in 11 states: Arizona, Florida, Iowa, Louisiana, Minnesota, Montana, Nebraska, North Dakota, South Dakota, Virginia, and Wyoming.
During the performance period, CMS will waive current MTM program requirements for participating plans in the test regions.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More